MX2018004160A - Secuencias 3´ utr para estabilización de arn. - Google Patents

Secuencias 3´ utr para estabilización de arn.

Info

Publication number
MX2018004160A
MX2018004160A MX2018004160A MX2018004160A MX2018004160A MX 2018004160 A MX2018004160 A MX 2018004160A MX 2018004160 A MX2018004160 A MX 2018004160A MX 2018004160 A MX2018004160 A MX 2018004160A MX 2018004160 A MX2018004160 A MX 2018004160A
Authority
MX
Mexico
Prior art keywords
rna
stabilization
utr sequences
present
mrna
Prior art date
Application number
MX2018004160A
Other languages
English (en)
Inventor
Beissert Tim
Sahin Ugur
Alexander Poleganov Marco
Fesser Stephanie
Orlandini Von Niessen Alexandra
Kuhn Andreas
Vallazza Britta
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of MX2018004160A publication Critical patent/MX2018004160A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B13/00—Details of tables or desks
    • A47B13/02—Underframes
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B3/00—Folding or stowable tables
    • A47B3/002—Folding or stowable tables with foldable underframe
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B33/00—Kitchen or dish-washing tables
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B43/00—Cabinets, racks or shelf units, characterised by features enabling folding of the cabinet or the like
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B77/00—Kitchen cabinets
    • A47B77/02—General layout, e.g. relative arrangement of compartments, working surface or surfaces, supports for apparatus
    • A47B77/022—Work tops
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B77/00—Kitchen cabinets
    • A47B77/04—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts
    • A47B77/06—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts for incorporating sinks, with or without draining boards, splash-backs, or the like
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B77/00—Kitchen cabinets
    • A47B77/04—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts
    • A47B77/08—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts for incorporating apparatus operated by power, including water power; for incorporating apparatus for cooking, cooling, or laundry purposes
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B77/00—Kitchen cabinets
    • A47B77/04—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts
    • A47B77/16—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts by adaptation of compartments or drawers for receiving or holding foodstuffs; by provision of rotatable or extensible containers for foodstuffs
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B77/00—Kitchen cabinets
    • A47B77/04—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts
    • A47B77/18—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts by special arrangements for accommodating removable containers
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B95/00—Fittings for furniture
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B95/00—Fittings for furniture
    • A47B95/008—Suspension fittings for cabinets to be hung on walls
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47C—CHAIRS; SOFAS; BEDS
    • A47C4/00—Foldable, collapsible or dismountable chairs
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47C—CHAIRS; SOFAS; BEDS
    • A47C4/00—Foldable, collapsible or dismountable chairs
    • A47C4/04—Folding chairs with inflexible seats
    • A47C4/08—Folding chairs with inflexible seats having a frame made of wood or plastics
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47C—CHAIRS; SOFAS; BEDS
    • A47C7/00—Parts, details, or accessories of chairs or stools
    • A47C7/002—Chair or stool bases
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47C—CHAIRS; SOFAS; BEDS
    • A47C7/00—Parts, details, or accessories of chairs or stools
    • A47C7/002—Chair or stool bases
    • A47C7/006—Chair or stool bases with castors
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47K—SANITARY EQUIPMENT NOT OTHERWISE PROVIDED FOR; TOILET ACCESSORIES
    • A47K3/00—Baths; Douches; Appurtenances therefor
    • A47K3/28—Showers or bathing douches
    • A47K3/283—Fixed showers
    • A47K3/284—Pre-fabricated shower cabinets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60B—VEHICLE WHEELS; CASTORS; AXLES FOR WHEELS OR CASTORS; INCREASING WHEEL ADHESION
    • B60B33/00—Castors in general; Anti-clogging castors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • E—FIXED CONSTRUCTIONS
    • E04—BUILDING
    • E04H—BUILDINGS OR LIKE STRUCTURES FOR PARTICULAR PURPOSES; SWIMMING OR SPLASH BATHS OR POOLS; MASTS; FENCING; TENTS OR CANOPIES, IN GENERAL
    • E04H1/00—Buildings or groups of buildings for dwelling or office purposes; General layout, e.g. modular co-ordination or staggered storeys
    • E04H1/12—Small buildings or other erections for limited occupation, erected in the open air or arranged in buildings, e.g. kiosks, waiting shelters for bus stops or for filling stations, roofs for railway platforms, watchmen's huts or dressing cubicles
    • E04H1/125—Small buildings, arranged in other buildings
    • E04H1/1266—Cubicles for dressing; Toilets
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
    • F16C11/00—Pivots; Pivotal connections
    • F16C11/04—Pivotal connections
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B3/00—Folding or stowable tables
    • A47B3/002—Folding or stowable tables with foldable underframe
    • A47B2003/006—Folding or stowable tables with foldable underframe having X/Y-crossed legs rotating around a central vertical axis
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B2200/00—General construction of tables or desks
    • A47B2200/0011—Underframes
    • A47B2200/0017—Nodal leg assembly for table
    • A47B2200/0018—Nodal leg assembly for table in two parts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Architecture (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Mechanical Engineering (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Civil Engineering (AREA)
  • Sustainable Development (AREA)

Abstract

La presente invención se refiere a la estabilización de ARN, en particular ARNm, y un incremento en la traducción de ARNm. La presente invención se refiere en particular a una modificación de ARN, en particular ARN transcrito in vitro, que da por resultado estabilidad incrementada de transcripto y/o eficiencia incrementada de traducción. De acuerdo a la invención, se demostró que ciertas secuencias en la región 3'-no traducida (UTR) de una molécula de ARN mejora la estabilidad y eficiencia de traducción.
MX2018004160A 2015-10-07 2016-10-05 Secuencias 3´ utr para estabilización de arn. MX2018004160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2015/073180 WO2017059902A1 (en) 2015-10-07 2015-10-07 3' utr sequences for stabilization of rna
PCT/EP2016/073814 WO2017060314A2 (en) 2015-10-07 2016-10-05 3' utr sequences for stabilization of rna

Publications (1)

Publication Number Publication Date
MX2018004160A true MX2018004160A (es) 2018-08-01

Family

ID=54293227

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004160A MX2018004160A (es) 2015-10-07 2016-10-05 Secuencias 3´ utr para estabilización de arn.
MX2021000250A MX2021000250A (es) 2015-10-07 2018-04-05 Secuencias 3 utr para estabilizacion de arn.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000250A MX2021000250A (es) 2015-10-07 2018-04-05 Secuencias 3 utr para estabilizacion de arn.

Country Status (26)

Country Link
US (2) US11492628B2 (es)
EP (3) EP3636764B1 (es)
JP (5) JP7084302B2 (es)
KR (2) KR102363368B1 (es)
CN (1) CN108291230B (es)
AU (3) AU2016335029B2 (es)
BR (2) BR122021025194B1 (es)
CA (2) CA2998554C (es)
CY (2) CY1122347T1 (es)
DK (2) DK3337902T3 (es)
ES (2) ES2866224T3 (es)
HK (2) HK1256701A1 (es)
HR (2) HRP20191907T1 (es)
HU (2) HUE055152T2 (es)
IL (3) IL293020A (es)
LT (2) LT3337902T (es)
MX (2) MX2018004160A (es)
NZ (1) NZ740946A (es)
PL (2) PL3636764T3 (es)
PT (2) PT3337902T (es)
RS (2) RS61684B1 (es)
RU (1) RU2720934C2 (es)
SG (1) SG10201912558YA (es)
SI (2) SI3636764T1 (es)
WO (2) WO2017059902A1 (es)
ZA (1) ZA201800835B (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US11253601B2 (en) 2016-07-11 2022-02-22 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
AU2018318135A1 (en) * 2017-08-15 2020-03-05 Intellia Therapeutics, Inc. Stabilized nucleic acids encoding messenger ribonucleic acid (MRNA)
CN111741764A (zh) 2018-02-12 2020-10-02 生物技术Rna制药有限公司 使用细胞因子编码rna的治疗
EP3788155A1 (en) * 2018-05-01 2021-03-10 Wake Forest University Health Sciences Lentiviral-based vectors and related systems and methods for eukaryotic gene editing
WO2020020783A1 (en) 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
CN115120716A (zh) 2019-01-14 2022-09-30 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
US20220125836A1 (en) 2019-02-08 2022-04-28 Biontech Cell & Gene Therapies Gmbh Treatment involving car-engineered t cells and cytokines
JP2022525921A (ja) 2019-03-18 2022-05-20 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー 免疫エフェクタ細胞の特異的活性化のためのインターロイキン２受容体（ｉｌ２ｒ）およびインターロイキン２（ｉｌ２）バリアント
WO2020200481A1 (en) 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Treatment involving interleukin-2 (il2) and interferon (ifn)
TW202115105A (zh) 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
CN114729369A (zh) * 2019-08-29 2022-07-08 苏黎世大学 最小mRNA及其用途
WO2021081261A1 (en) * 2019-10-22 2021-04-29 The Regents Of The University Of California Modulation of engineered immune cell receptor translation using noncoding sequence elements
AU2021212197A1 (en) 2020-01-31 2022-08-04 BioNTech SE Methods of inducing neoepitope-specific T cells with a PD-1 axis binding antagonist and an RNA vaccine
EP4103228A1 (en) 2020-02-13 2022-12-21 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
CA3171370A1 (en) 2020-03-16 2021-09-23 Ugur Sahin Antigen-specific t cell receptors and t cell epitopes
KR102462990B1 (ko) * 2020-03-17 2022-11-07 에이비온 주식회사 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물
EP4126947A1 (en) 2020-03-30 2023-02-08 BioNTech SE Rna compositions targeting claudin-18.2
WO2021197589A1 (en) 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
IL297414A (en) 2020-04-22 2022-12-01 Pfizer Vaccine against the corona virus
GB202307565D0 (en) * 2020-04-22 2023-07-05 BioNTech SE Coronavirus vaccine
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
EP4182924A1 (en) 2020-07-17 2023-05-24 Genentech, Inc. Attention-based neural network to predict peptide binding, presentation, and immunogenicity
EP4192859A1 (en) 2020-08-06 2023-06-14 BioNTech SE Binding agents for coronavirus s protein
MX2023002670A (es) 2020-09-08 2023-05-08 Genentech Inc Sistemas y procedimientos para producir composiciones farmaceuticas usando bombas peristalticas y amortiguadores.
TW202227478A (zh) 2020-09-15 2022-07-16 德商拜恩迪克公司 對細胞靶向遞送的藥劑及方法
EP4203997A1 (en) 2020-10-26 2023-07-05 Pécsi Tudományegyetem Vaccine platform
JP2023547947A (ja) 2020-11-11 2023-11-14 ビオンテック・ソシエタス・エウロパエア プログラム細胞死－１タンパク質に対するモノクローナル抗体および医薬におけるその使用
WO2022106860A1 (en) 2020-11-20 2022-05-27 Pécsi Tudományegyetem Recombinant peptides for use in therapy
WO2022122689A1 (en) 2020-12-09 2022-06-16 BioNTech SE Rna manufacturing
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) * 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CN114717230A (zh) * 2021-01-05 2022-07-08 麦塞拿治疗(香港)有限公司 成纤维细胞生长因子mRNA的无细胞和无载体体外RNA转录方法和核酸分子
WO2022223617A1 (en) 2021-04-20 2022-10-27 BioNTech SE Virus vaccine
JP2024518335A (ja) 2021-04-26 2024-05-01 アンスティチュ パスツール ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用
EP4334943A1 (en) 2021-05-04 2024-03-13 BioNTech SE Technologies for early detection of variants of interest
EP4351633A1 (en) 2021-06-08 2024-04-17 Biontech Cell & Gene Therapies Gmbh Agents and methods for activation and targeting of immune effector cells
KR20230000471A (ko) * 2021-06-24 2023-01-02 한미약품 주식회사 비천연 5'-비번역 영역 및 3'-비번역 영역 및 그의 용도
EP4370551A1 (en) 2021-07-15 2024-05-22 BioNTech SE Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
WO2023008793A1 (ko) * 2021-07-27 2023-02-02 에스케이바이오사이언스(주) 단백질 발현을 위한 mrna와 이를 위한 주형
WO2023006920A1 (en) 2021-07-29 2023-02-02 BioNTech SE Compositions and methods for treatment of melanoma
EP4392140A1 (en) 2021-08-24 2024-07-03 BioNTech SE In vitro transcription technologies
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
CA3234490A1 (en) * 2021-10-07 2023-04-13 Precision NanoSystems ULC Rna vaccine lipid nanoparticles
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023061550A1 (en) 2021-10-11 2023-04-20 BioNTech SE Therapeutic rna for lung cancer
TW202333803A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性ｒｎａ（一）
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
CN118302189A (zh) 2021-10-21 2024-07-05 生物技术欧洲股份公司 冠状病毒疫苗
WO2023067126A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide compounds and complexes
EP4169580A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
EP4169534A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide complexes and uses
EP4285933A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
EP4169579A1 (en) 2021-10-22 2023-04-26 BioNTech SE Disulfide oligosaccharide compounds and complexes
WO2023067124A1 (en) 2021-10-22 2023-04-27 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4285932A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
WO2023067123A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide complexes and uses
EP4286004A1 (en) 2022-05-30 2023-12-06 BioNTech SE Disulfide oligosaccharide compounds and complexes
AU2022369405A1 (en) 2021-10-22 2024-05-09 BioNTech SE Oligosaccharide compounds and complexes
EP4286003A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
WO2023067125A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide complexes and uses
EP4286394A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4186528A1 (en) 2021-11-30 2023-05-31 BioNTech SE Oligosaccharide complexes and uses
EP4238577A3 (en) 2021-10-22 2023-12-06 BioNTech SE Compositions for administration of different doses of rna
EP4169578A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
WO2023073190A1 (en) 2021-10-28 2023-05-04 BioNTech SE Rna constructs and uses thereof
WO2023083434A1 (en) 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
EP4226938A3 (en) 2021-11-29 2023-11-01 BioNTech SE Coronavirus vaccine
WO2024046572A1 (en) 2022-09-01 2024-03-07 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
AU2022405694A1 (en) 2021-12-09 2024-07-04 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
WO2023126053A1 (en) 2021-12-28 2023-07-06 BioNTech SE Lipid-based formulations for administration of rna
WO2023147090A1 (en) 2022-01-27 2023-08-03 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2023147091A1 (en) 2022-01-28 2023-08-03 BioNTech SE Coronavirus vaccine
WO2023214801A1 (ko) * 2022-05-03 2023-11-09 단국대학교 산학협력단 단백질의 발현 수준 및 발현 위치 조절을 위한 utr 서열 및 이를 포함하는 mrna 서열
US11932693B2 (en) 2022-05-12 2024-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2023218431A1 (en) 2022-05-13 2023-11-16 BioNTech SE Rna compositions targeting hiv
WO2023230295A1 (en) 2022-05-25 2023-11-30 BioNTech SE Rna compositions for delivery of monkeypox antigens and related methods
WO2023232747A1 (en) 2022-05-30 2023-12-07 BioNTech SE Complexes for delivery of nucleic acids
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
WO2024028445A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024027910A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
CN117660494A (zh) * 2022-09-07 2024-03-08 远大赛威信生命科学(南京)有限公司 用于表达水痘-带状疱疹病毒抗原蛋白的mRNA及其用途
WO2024056856A1 (en) 2022-09-15 2024-03-21 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna
WO2024064931A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024064934A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024068674A1 (en) 2022-09-26 2024-04-04 BioNTech SE Nucleic acid complexes and uses thereof
WO2024074634A1 (en) * 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024074211A1 (en) * 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024086575A1 (en) 2022-10-17 2024-04-25 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024084462A1 (en) 2022-10-21 2024-04-25 BioNTech SE Nucleic acid complexes and uses thereof
WO2024107754A1 (en) 2022-11-15 2024-05-23 Genentech, Inc. Selection of diverse candidate peptides for peptide therapeutics
WO2024137589A2 (en) 2022-12-20 2024-06-27 Genentech, Inc. Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
CN117535295B (zh) * 2024-01-09 2024-04-26 艾斯拓康医药科技(北京)有限公司 一种优化的3`utr序列及其应用

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
ES2121803T3 (es) 1987-05-20 1998-12-16 Novartis Ag Plantas de zea mays y plantas transgenicas de zea mays generadas a partir de protoplastos o celulas derivadas de protoplastos.
RU2126047C1 (ru) 1987-05-29 1999-02-10 Новартис Аг Способ получения растений zea mays l., устойчивых к повреждениям, вызываемым насекомыми
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991019806A1 (en) 1990-06-18 1991-12-26 Monsanto Company Increased starch content in plants
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
NL9300646A (nl) 1992-12-28 1994-07-18 Stichting Scheikundig Onderzoe Werkwijze voor het verkrijgen van transgene planten welke een gemodificeerd fructaan-patroon vertonen.
AU5843794A (en) 1992-12-28 1994-07-19 Stichting Scheikundig Onderzoek In Nederland Method for obtaining transgenic plants showing a modified fructan pattern
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
DE69723434T2 (de) 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
EP0938298B1 (en) 1996-09-13 2002-12-04 Lipoxen Technologies Limited Liposome-based composition
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
EP1029050A1 (en) 1997-11-06 2000-08-23 Roche Diagnostics GmbH Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
JP2002526421A (ja) 1998-10-05 2002-08-20 ジェンザイム・コーポレーション 癌細胞に差別的に発現する癌ワクチン設計のための遺伝子
WO2000050592A1 (en) 1999-02-24 2000-08-31 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
BR0010322A (pt) 1999-05-06 2002-04-09 Univ Wake Forest Vetor de expressão, vacina e seu método de uso para eliciar uma resposta imune dirigida contra um antìgeno em um mamìfero
JP5640237B2 (ja) 1999-11-30 2014-12-17 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 癌関連抗原をコードする単離された核酸分子、その抗原そのものおよびその使用
ATE366582T1 (de) 1999-12-28 2007-08-15 Pharmexa Inc Optimierte minigene und dadurch kodierte peptide
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
AR044724A1 (es) 2000-03-27 2005-10-05 Syngenta Participations Ag Promotores del virus de la rizadura amarilla del cestrum
CA2412026A1 (en) 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
DE50214200D1 (de) * 2001-06-05 2010-03-25 Curevac Gmbh Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
EP1444326A4 (en) * 2001-08-24 2006-06-28 Advanced Cell Tech Inc SCREENING ASSAYS FOR IDENTIFICATION OF AGENTS INDUCING DIFFERENTIATION, AND PRODUCTION OF CELLS DIFFERENTIATED FOR CELL THERAPY
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
KR20050016410A (ko) * 2002-05-17 2005-02-21 베일러 칼리지 오브 메디신 도세탁셀 약제민감성 및 약제내성을 예측하는 특징적인유전자 발현 패턴
ATE519115T1 (de) 2002-06-13 2011-08-15 Merck Patent Gmbh Verfahren für die identifizierung von allo- antigenen und ihre verwendung für krebstherapie und transplantation
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US7393653B2 (en) 2002-09-06 2008-07-01 The Burnham Institute Methods of modulating cell death based on the Bit1/AES regulatory pathway
KR100710519B1 (ko) 2002-10-09 2007-04-24 (주)씨아이디 일본뇌염 바이러스의 신규한 전체-길이의 게놈 ＲＮＡ 및상기 ＪＥＶ 게놈 ＲＮＡ에 대한 감염성이 있는 ＪＥＶｃＤＮＡ 및 이것의 용도
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP2286794B8 (en) 2003-10-15 2016-06-01 SynCore Biotechnology CO., LTD Use of cationic liposomes comprising paclitaxel
CN1898569A (zh) 2003-10-24 2007-01-17 伊缪因艾德有限公司 治疗方法
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
WO2006071990A2 (en) 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
GB0507997D0 (en) 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
CN101213297B (zh) 2005-05-09 2013-02-13 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
ES2735531T3 (es) 2005-08-23 2019-12-19 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
DE602005026186D1 (de) * 2005-12-12 2011-03-10 Riyadh Sa 3-nichttranslatierte hybridbereiche mit eignung zur effizienten proteinexpression in säugerzellen
EP1994181A4 (en) 2006-02-27 2010-05-19 Univ Arizona IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
US20090275633A1 (en) 2006-04-13 2009-11-05 Oncomethylome Sciences Sa Novel Tumour Suppressor
US20090304711A1 (en) 2006-09-20 2009-12-10 Drew Pardoll Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
WO2008112127A2 (en) * 2007-03-08 2008-09-18 Switchgear Genomics Functional arrays for high throughput characterization of regulatory elements in untranslated regions of genes
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
CA2715078C (en) 2007-09-26 2019-07-23 Intrexon Corporation Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CN103396415B (zh) 2008-03-24 2016-08-10 4Sc股份有限公司 新的取代的咪唑并喹啉化合物
CA2721366C (en) 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation of an immune response by enantiomers of cationic lipids
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
DK2459231T3 (en) 2009-07-31 2016-09-05 Ethris Gmbh RNA with a combination of unmodified and modified nucleotides for protein expression
WO2011075838A1 (en) 2009-12-21 2011-06-30 Audigen Inc. Method of treating or preventing hearing loss
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
KR102095670B1 (ko) 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
DE102011102734A1 (de) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
RU2491343C1 (ru) 2011-12-23 2013-08-27 Общество с ограниченной ответственностью "Биотехнологический центр трансгенеза в фарминдустрии "Трансгенфарм" Генетические конструкции ltf3, ltf5, ltf7, ltf10, ltf11 для получения рекомбинантного лактоферрина человека (варианты)
US20150030576A1 (en) 2012-01-10 2015-01-29 Moderna Therapeutics, Inc. Methods and compositions for targeting agents into and across the blood-brain barrier
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
EP3072898A1 (en) 2012-02-20 2016-09-28 Universita' degli Studi di Milano Homo- and heterodimeric smac mimetic compounds as apoptosis inducers
JP6295512B2 (ja) 2012-03-15 2018-03-20 株式会社豊田中央研究所 酵母における外来遺伝子の発現産物の生産方法、酵母における発現調節剤及びその利用
MX358706B (es) * 2012-03-27 2018-08-31 Curevac Ag Moleculas de acido nucleico artificiales que comprenden un top 5´utr.
DK3578659T3 (da) * 2012-03-27 2024-02-05 CureVac SE Kunstige nukelinsyremolekyler til forbedret protein- eller peptidekspression
SG10201607962RA (en) * 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
CN104662171B (zh) 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 个性化癌症疫苗和过继免疫细胞治疗
JP2015524672A (ja) 2012-08-17 2015-08-27 ダウ アグロサイエンシィズ エルエルシー 植物における導入遺伝子発現のためのトウモロコシ非翻訳領域の使用
RU2711249C2 (ru) 2012-11-01 2020-01-15 Фэктор Байосайенс Инк. Способы и продукты для экспрессии белков в клетках
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
WO2014144711A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
KR102341899B1 (ko) 2013-04-07 2021-12-21 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
WO2014184684A2 (en) 2013-05-16 2014-11-20 Oslo Universitetssykehus Hf Methods and biomarkers for detection of hematological cancers
RU2535871C1 (ru) 2013-07-10 2014-12-20 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") Плазмида для экспрессии в клетке китайского хомячка, клетка китайского хомячка - продуцент белка с Gla-доменом и способ получения белка с Gla-доменом
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3043826A4 (en) 2013-09-13 2017-05-24 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
WO2015043613A1 (en) 2013-09-26 2015-04-02 Biontech Ag Particles comprising a shell with rna
WO2015051173A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc Polynucleotide molecules and uses thereof
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
WO2015085318A2 (en) 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Targeted adaptive vaccines
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
KR102399799B1 (ko) * 2013-12-30 2022-05-18 큐어백 아게 인공 핵산 분자
JP6584414B2 (ja) * 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
JP2017507703A (ja) 2014-02-05 2017-03-23 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ カニューレ、注射または注入装置、およびカニューレまたは注射もしくは注入装置を使用する方法
HUE051311T2 (hu) * 2014-03-09 2021-03-01 Univ Pennsylvania Ornitin transzkarbamiláz (TC) deficiencia kezelésében alkalmas készítmények
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016005004A1 (en) * 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
ES2791152T3 (es) * 2014-12-12 2020-11-03 Curevac Ag Moléculas de ácido nucleico artificiales para una expresión proteica mejorada
EP3240558A1 (en) 2014-12-30 2017-11-08 CureVac AG Artificial nucleic acid molecules
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
WO2017059902A1 (en) * 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna

Also Published As

Publication number Publication date
ES2866224T3 (es) 2021-10-19
LT3636764T (lt) 2021-05-10
IL284651B (en) 2022-06-01
EP3636764B1 (en) 2021-03-03
KR20220025195A (ko) 2022-03-03
JP7084565B2 (ja) 2022-06-15
RU2018112325A (ru) 2019-11-07
HRP20191907T1 (hr) 2020-02-07
CN108291230B (zh) 2022-12-20
PT3337902T (pt) 2019-10-30
AU2023278107A1 (en) 2024-01-04
IL258074B (en) 2021-07-29
PL3337902T3 (pl) 2020-01-31
PT3636764T (pt) 2021-03-25
JP2021129563A (ja) 2021-09-09
JP2018530332A (ja) 2018-10-18
EP3868885A1 (en) 2021-08-25
JP6844060B1 (ja) 2021-03-17
AU2021206886B2 (en) 2023-12-14
JP7084302B2 (ja) 2022-06-14
HK1256701A1 (zh) 2019-10-04
PL3636764T3 (pl) 2021-07-05
LT3337902T (lt) 2019-12-10
EP3337902B1 (en) 2019-09-25
IL293020A (en) 2022-07-01
MX2021000250A (es) 2021-04-12
US20230272406A1 (en) 2023-08-31
RU2018112325A3 (es) 2019-11-07
CY1124066T1 (el) 2022-05-27
BR112018003486A2 (pt) 2018-09-25
CN108291230A (zh) 2018-07-17
AU2021206886A1 (en) 2021-08-12
IL258074A (en) 2018-05-31
JP2021048847A (ja) 2021-04-01
SG10201912558YA (en) 2020-02-27
RS59538B1 (sr) 2019-12-31
SI3337902T1 (sl) 2019-12-31
RS61684B1 (sr) 2021-05-31
AU2016335029A1 (en) 2018-04-19
CY1122347T1 (el) 2021-01-27
HUE055152T2 (hu) 2021-11-29
AU2016335029B2 (en) 2021-04-29
KR20180057647A (ko) 2018-05-30
CA2998554C (en) 2024-04-30
NZ740946A (en) 2022-08-26
BR112018003486B1 (pt) 2023-09-26
EP3337902A2 (en) 2018-06-27
HRP20210449T1 (hr) 2021-10-01
ES2753201T8 (es) 2020-04-16
SI3636764T1 (sl) 2021-07-30
BR122021025194A8 (pt) 2023-01-31
JP7277506B2 (ja) 2023-05-19
BR122021025194A2 (es) 2018-09-25
HK1258262A1 (zh) 2019-11-08
KR102363368B1 (ko) 2022-02-16
ES2753201T3 (es) 2020-04-07
CA3223575A1 (en) 2017-04-13
US11492628B2 (en) 2022-11-08
RU2720934C2 (ru) 2020-05-14
WO2017060314A2 (en) 2017-04-13
WO2017059902A1 (en) 2017-04-13
US20190071682A1 (en) 2019-03-07
CA2998554A1 (en) 2017-04-13
JP2022050390A (ja) 2022-03-30
DK3337902T3 (da) 2019-11-04
WO2017060314A3 (en) 2017-05-18
DK3636764T3 (da) 2021-03-22
JP2021048848A (ja) 2021-04-01
EP3636764A1 (en) 2020-04-15
IL284651A (en) 2021-08-31
ZA201800835B (en) 2020-05-27
BR122021025194B1 (pt) 2023-09-26
HUE046982T2 (hu) 2020-04-28

Similar Documents

Publication Publication Date Title
MX2018004160A (es) Secuencias 3´ utr para estabilización de arn.
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
AU2020201465A1 (en) Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
EP4349404A3 (en) Respiratory virus vaccines
MX2018014152A (es) Composiciones y métodos para tratar la enfermedad de huntington.
MX2016002044A (es) Composiciones y metodos para modular el acido ribonucleico.
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
MX2019006475A (es) Sistemas y métodos para dirección con arn guía puntual (arngp) de adn endógeno y fuente.
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
PH12016502050B1 (en) Homovanillinic acid ester, in particular, for creating a hot and/or pungent taste sensation
MX2021010716A (es) Composiciones y metodos para inhibir la expresion del gen lect2.
MX2022001017A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
PH12018500155A1 (en) Recombinant orf virus vector
IN2015DN02699A (es)
MX2015013036A (es) Composiciones promotoras.